Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

Overview

The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.

Determination of safety is the most important goal of this first study with C326. Other goals of the study are to examine: * pharmacokinetics (change in serum concentrations over time), * biological activity (change in blood markers relecting activity of Crohn's Disease), * effects on symptoms of Crohn's disease. Participants may receive either a single or several intravenous infusions of C326 or matching placebo.

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Central Contacts